

# Nithya Ramnath

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10552494/publications.pdf>

Version: 2024-02-01

76  
papers

5,985  
citations

101543

36  
h-index

76900

74  
g-index

77  
all docs

77  
docs citations

77  
times ranked

10576  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Integrative clinical genomics of metastatic cancer. <i>Nature</i> , 2017, 548, 297-303.   | 27.8 | 685       |
| 2  | Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. <i>Nature Nanotechnology</i> , 2013, 8, 735-741.   | 31.5 | 487       |
| 3  | Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. <i>Nature Medicine</i> , 2021, 27, 152-164.   | 30.7 | 451       |
| 4  | Induction Chemotherapy Followed by Chemoradiotherapy Compared With Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Non-Small-Cell Lung Cancer: Cancer and Leukemia Group B. <i>Journal of Clinical Oncology</i> , 2007, 25, 1698-1704. | 1.6  | 437       |
| 5  | Treatment of Stage III Non-small Cell Lung Cancer. <i>Chest</i> , 2013, 143, e314S-e340S.   | 0.8  | 381       |
| 6  | Reactive Oxygen Species in the Tumor Microenvironment: An Overview. <i>Cancers</i> , 2019, 11, 1191.  | 3.7  | 288       |
| 7  | Nuclear or cytoplasmic expression of survivin: What is the significance?. <i>International Journal of Cancer</i> , 2005, 114, 509-512.  | 5.1  | 225       |
| 8  | Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. <i>Oncotarget</i> , 2014, 5, 12383-12397.  | 1.8  | 175       |
| 9  | Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. <i>Cancer Research</i> , 2019, 79, 3940-3951.  | 0.9  | 154       |
| 10 | Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers. <i>Cancer Research</i> , 2017, 77, 5194-5206.   | 0.9  | 139       |
| 11 | MCM2 Is an Independent Predictor of Survival in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 4259-4266.  | 1.6  | 123       |
| 12 | A Radial Flow Microfluidic Device for Ultra-High-Throughput Affinity-Based Isolation of Circulating Tumor Cells. <i>Small</i> , 2014, 10, 4895-4904.  | 10.0 | 115       |
| 13 | A Novel Serum 4-microRNA Signature for Lung Cancer Detection. <i>Scientific Reports</i> , 2015, 5, 12464.   | 3.3  | 111       |
| 14 | KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1513-1522.  | 1.1  | 108       |
| 15 | Isolation and Profiling of Circulating Tumor-Associated Exosomes Using Extracellular Vesicular Lipid-Protein Binding Affinity Based Microfluidic Device. <i>Small</i> , 2019, 15, e1903600.   | 10.0 | 106       |
| 16 | Matrix metalloproteinase inhibitors. <i>Current Oncology Reports</i> , 2004, 6, 96-102.   | 4.0  | 100       |
| 17 | Effects of Cigarette Smoking on Metabolism and Effectiveness of Systemic Therapy for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 917-926.   | 1.1  | 99        |
| 18 | CYP24A1 Is an Independent Prognostic Marker of Survival in Patients with Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 817-826.  | 7.0  | 96        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | A MicroRNA Cluster at 14q32 Drives Aggressive Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 3107-3117.   | 7.0  | 92        |
| 20 | PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer. <i>Scientific Reports</i> , 2019, 9, 566.  | 3.3  | 90        |
| 21 | Up-Regulation of Peroxiredoxin 1 in Lung Cancer and Its Implication as a Prognostic and Therapeutic Target. <i>Clinical Cancer Research</i> , 2008, 14, 2326-2333.  | 7.0  | 82        |
| 22 | Elevated Peroxiredoxin 1, but not NF-E2-Related Factor 2, Is an Independent Prognostic Factor for Disease Recurrence and Reduced Survival in Stage I Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 3875-3882.   | 7.0  | 73        |
| 23 | HER-2/ neu Protein Expression and Gene Alteration in Stage I-III A Non-Small-Cell Lung Cancer: A Study of 140 Cases Using a Combination of High Throughput Tissue Microarray, Immunohistochemistry, and Fluorescent In Situ Hybridization. <i>Diagnostic Molecular Pathology</i> , 2003, 12, 201-211.                 | 2.1  | 71        |
| 24 | Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry. <i>Modern Pathology</i> , 2004, 17, 430-439.  | 5.5  | 67        |
| 25 | High-Throughput Label-Free Isolation of Heterogeneous Circulating Tumor Cells and CTC Clusters from Non-Small-Cell Lung Cancer Patients. <i>Cancers</i> , 2020, 12, 127.  | 3.7  | 60        |
| 26 | Characterization of vitamin D receptor (VDR) in lung adenocarcinoma. <i>Lung Cancer</i> , 2012, 77, 265-271.  | 2.0  | 58        |
| 27 | Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. <i>Cancer Medicine</i> , 2016, 5, 2567-2578.  | 2.8  | 56        |
| 28 | Pulmonary venous blood sampling significantly increases the yield of circulating tumor cells in early-stage lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 151, 852-858.  | 0.8  | 53        |
| 29 | Upregulation of the Tissue Inhibitor of Metalloproteinase-1 Protein Is Associated With Progression of Human Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 3218-3229.  | 1.6  | 51        |
| 30 | On-Chip Biogenesis of Circulating NK Cell-Derived Exosomes in Non-Small Cell Lung Cancer Exhibits Antitumoral Activity. <i>Advanced Science</i> , 2021, 8, 2003747.   | 11.2 | 50        |
| 31 | Phase II Trial of Imatinib Maintenance Therapy After Irinotecan and Cisplatin in Patients With c-KIT-Positive, Extensive-Stage Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2010, 11, 223-227.   | 2.6  | 48        |
| 32 | Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future Directions. <i>Frontiers in Oncology</i> , 2015, 5, 209.  | 2.8  | 48        |
| 33 | Changes in Global Function and Regional Ventilation and Perfusion on SPECT During the Course of Radiotherapy in Patients With Non-Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e631-e638.   | 0.8  | 46        |
| 34 | Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. <i>Oncotarget</i> , 2017, 8, 89848-89866.  | 1.8  | 45        |
| 35 | Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy Compared with Chemoradiotherapy Alone for Unresectable Stage III Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1117-1125. | 1.1  | 40        |
| 36 | In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 881-891.  | 2.3  | 39        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Semiquantification and Classification of Local Pulmonary Function by V/Q Single Photon Emission Computed Tomography in Patients with Non-small Cell Lung Cancer: Potential Indication for Radiotherapy Planning. <i>Journal of Thoracic Oncology</i> , 2011, 6, 71-78. | 1.1 | 37        |
| 38 | Expanded Circulating Tumor Cells from a Patient with ALK- Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study. <i>Journal of Thoracic Oncology</i> , 2017, 12, 397-402.          | 1.1 | 37        |
| 39 | Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes. <i>Diabetes Care</i> , 2022, 45, 1170-1176.  | 8.6 | 33        |
| 40 | Development and Validation of a Quantitative Real-Time Polymerase Chain Reaction Classifier for Lung Cancer Prognosis. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1481-1487.   | 1.1 | 30        |
| 41 | Phase II Trial of Sunitinib Maintenance Therapy After Platinum-Based Chemotherapy in Patients with Extensive-Stage Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1117-1120.   | 1.1 | 29        |
| 42 | Epigenetic Regulation of Vitamin D Metabolism in Human Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2014, 9, 473-482.  | 1.1 | 28        |
| 43 | Loss of cables protein expression in human non-“small cell lung cancer: A tissue microarray study. <i>Human Pathology</i> , 2003, 34, 143-149.   | 2.0 | 27        |
| 44 | Pneumonectomy for Bronchogenic Carcinoma: Analysis of Factors Predicting Survival. <i>Annals of Thoracic Surgery</i> , 2007, 83, 1831-1836.  | 1.3 | 27        |
| 45 | Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-“Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 915-921.                      | 4.9 | 27        |
| 46 | Apoptosis-Related (Survivin, Bcl-2), Tumor Suppressor Gene (p53), Proliferation (Ki-67), and Non-Receptor Tyrosine Kinase (Src) Markers Expression and Correlation With Clinicopathologic Variables in 60 Thymic Neoplasms. <i>Chest</i> , 2009, 136, 220-228.         | 0.8 | 26        |
| 47 | Oncogenic Potential of CYP24A1 in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 269-280.  | 1.1 | 23        |
| 48 | Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 614.   | 3.7 | 23        |
| 49 | Phase II Study of Neoadjuvant Chemotherapy With Gemcitabine and Vinorelbine in Resectable Non-small Cell Lung Cancer. <i>Chest</i> , 2005, 128, 3467-3474.   | 0.8 | 21        |
| 50 | The Lung Microbiome: A Central Mediator of Host Inflammation and Metabolism in Lung Cancer Patients?. <i>Cancers</i> , 2021, 13, 13.   | 3.7 | 21        |
| 51 | MAP3K3 expression in tumor cells and tumor-infiltrating lymphocytes is correlated with favorable patient survival in lung cancer. <i>Scientific Reports</i> , 2015, 5, 11471.  | 3.3 | 19        |
| 52 | Cigarette Smoking and Gemcitabine-Induced Neutropenia in Advanced Solid Tumors. <i>Oncology</i> , 2013, 85, 216-222.   | 1.9 | 17        |
| 53 | KRAS-G12C Mutation is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, e9-e10.   | 1.1 | 16        |
| 54 | Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2021, 4, e210980.   | 5.9 | 16        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Validation of a serum 4-microRNA signature for the detection of lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 636-648.  | 2.8 | 15        |
| 56 | Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer. <i>Lung Cancer</i> , 2022, 163, 35-41.   | 2.0 | 15        |
| 57 | Phase II Study of Perioperative Chemotherapy with Cisplatin and Pemetrexed in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 222-230.   | 1.1 | 14        |
| 58 | Radiation-induced lung toxicity in non-small-cell lung cancer: Understanding the interactions of clinical factors and cytokines with the dose-toxicity relationship. <i>Radiotherapy and Oncology</i> , 2017, 125, 66-72.                           | 0.6 | 14        |
| 59 | Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 51, 227-230.  | 2.3 | 13        |
| 60 | A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 170-177.               | 0.8 | 13        |
| 61 | Vitamin D and lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2011, 5, 305-309.   | 2.5 | 12        |
| 62 | Optimizing the Detection of Circulating Markers to Aid in Early Lung Cancer Detection. <i>Cancers</i> , 2016, 8, 61.  | 3.7 | 12        |
| 63 | Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 559-564.   | 2.6 | 12        |
| 64 | Simultaneous Single Cell Gene Expression and EGFR Mutation Analysis of Circulating Tumor Cells Reveals Distinct Phenotypes in NSCLC. <i>Advanced Biology</i> , 2020, 4, e2000110.   | 3.0 | 12        |
| 65 | Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .  | 0.8 | 10        |
| 66 | Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2015, 6, 156.   | 2.3 | 8         |
| 67 | The cytochrome P450 enzyme CYP24A1 increases proliferation of mutant KRAS-dependent lung adenocarcinoma independent of its catalytic activity. <i>Journal of Biological Chemistry</i> , 2020, 295, 5906-5917.                                       | 3.4 | 7         |
| 68 | Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 752-758. | 0.8 | 5         |
| 69 | Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study. <i>Anti-Cancer Drugs</i> , 2008, 19, 749-752.  | 1.4 | 4         |
| 70 | Isolation of Circulating Biomarkers for Liquid Biopsy using Immunoaffinity-Based Stimuli-Responsive Hybrid Hydrogel Beads. <i>Analysis &amp; Sensing</i> , 2021, 1, 117-129.  | 2.0 | 3         |
| 71 | The "liquid biopsy" in non-small cell lung cancer "not quite ready for prime time use. <i>Translational Cancer Research</i> , 2016, 5, S632-S635.   | 1.0 | 3         |
| 72 | Molecular biomarkers and liquid biopsies in lung cancer. <i>Seminars in Oncology</i> , 2022, 49, 275-284.   | 2.2 | 2         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer. Scientific Reports, 2022, 12, .                               | 3.3 | 1         |
| 74 | Progress in the Treatment of Metastatic Nonâ€“Small-Cell Lung Cancer: Slow but Steady!. Clinical Lung Cancer, 2009, 10, 260-261.  | 2.6 | 0         |
| 75 | Characterization of pneumonia and other factors leading to poorer survival across all age groups in patients with non-small cell lung cancer (NSCLC). Journal of Thoracic Disease, 2021, 13, 986-994.                   | 1.4 | 0         |
| 76 | Epidermal Growth Factor Receptor Mutations Carried in Extracellular Vesicle-Derived Cargo Mirror Disease Status in Metastatic Non-small Cell Lung Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 724389. | 3.7 | 0         |